Plasmodium falciparum (P. falciparum) sporozoite challenge

OTHER2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Malaria

Phase 1

Trial to Evaluate CIS43LS in Healthy Adults

CompletedNCT04206332

National Institute of Allergy and Infectious Diseases (NIAID)Malaria

Start: 2020-01-07End: 2022-02-28Updated: 2023-04-18

Trial to Evaluate L9LS in Healthy Adults

CompletedNCT05019729

National Institute of Allergy and Infectious Diseases (NIAID)Malaria

Start: 2021-09-13End: 2022-09-19Updated: 2024-08-14

Related Papers

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.

2023-01-2521 citations

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

New England Journal of Medicine2022-08-03114 citations

A Monoclonal Antibody for Malaria Prevention

New England Journal of Medicine2021-08-11148 citations